Sanofi lifts sales potential of blockbuster drug to USD 14.5bn

Sales of drug Dupixent, which is in direct competition with Danish firm Leo Pharma’s drug Adtralza, are going so well that the company behind the treatment, Sanofi, has raised its sales expectations to USD 14.5bn.
Photo: Violeta Santos Moura/Reuters/Ritzau Scanpix
Photo: Violeta Santos Moura/Reuters/Ritzau Scanpix
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen

When Paul Hudson, a British national, took over at the helm of French pharmaceutical company Sanofi back in June 2019, it was said that multi-blockbuster Dupixent could reach top sales of USD 11bn.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading